Gynofem Healthcare
1 MAbout Gynofem Healthcare
A Comprehensive Overview of Price & Journey
Understanding Gynofem Healthcare Inception and Growth
Overview
Gynofem Healthcare Ltd. is a fast-growing Indian Pharmaceutical company engaged in developing and marketing a broad range of pharmaceutical products. The core strength of Gynofem lies in the development of Gynecological products. These products are specially designed to be of help to a mother willing to conceive and during her pregnancy. There are products designed by Gynofem to help those mothers unable to conceive due to clinical reasons, to conceive successfully and become a mother of a child. Gynofem products are of tremendous use to pregnant mothers, helping them to carry a healthy child. It helps mothers after their delivery and they nurse their babies to a healthy life with a complete regain of their normal health.
Gynofem Healthcare is a pharmaceutical and healthcare company specializing in women’s health and gynecological care. It primarily operates as a trading and distribution entity, supplying gynecological medicines, supplements, and wellness products to hospitals, clinics, and retail pharmacies. It belongs to the Industry of Pharmaceuticals & Healthcare. It was founded on May 27, 2016. Its Headquarters are in Indore, Madhya Pradesh, India. Its main focus is on Women's health, gynecology, fertility treatments, and wellness supplements
Products
-
Macova 2.5 Tablet
-
Rabifem-DSR Capsule
-
Save 9 Tablet
-
Z-Fem 500 Tablet
-
Derwin Gel
-
Dydrofast 10 Tablet
-
Etoder-P Tablet
-
& Many More
SHOW MORE...
Overview
Gynofem Healthcare Ltd. is a fast-growing Indian Pharmaceutical company engaged in developing and marketing a broad range of pharmaceutical products. The core strength of Gynofem lies in the development of Gynecological products. These products are specially designed to be of help to a mother willing to conceive and during her pregnancy. There are products designed by Gynofem to help those mothers unable to conceive due to clinical reasons, to conceive successfully and become a mother of a child. Gynofem products are of tremendous use to pregnant mothers, helping them to carry a healthy child. It helps mothers after their delivery and they nurse their babies to a healthy life with a complete regain of their normal health.
Gynofem Healthcare is a pharmaceutical and healthcare company specializing in women’s health and gynecological care. It primarily operates as a trading and distribution entity, supplying gynecological medicines, supplements, and wellness products to hospitals, clinics, and retail pharmacies. It belongs to the Industry of Pharmaceuticals & Healthcare. It was founded on May 27, 2016. Its Headquarters are in Indore, Madhya Pradesh, India. Its main focus is on Women's health, gynecology, fertility treatments, and wellness supplements
Products
-
Macova 2.5 Tablet
-
Rabifem-DSR Capsule
-
Save 9 Tablet
-
Z-Fem 500 Tablet
-
Derwin Gel
-
Dydrofast 10 Tablet
-
Etoder-P Tablet
-
& Many More
About Gynofem Healthcare
IPO Details, Price movement
Board of Directors
-
Nishikant Joshi, Director
-
Anurag Mendhe, Director
-
Kartikay Joshi, Director
MISSION STATEMENT
“Gynofem Healthcare Pvt. Ltd. is a company with a mission to build a stronger India in the future. Gynofem focuses on the health of a mother and a nursing mother, so that she remains healthy, gives birth to a healthy child, and hence helps build a stronger nation. Gynofem Healthcare is a company with a mission to combat malnutrition among mothers and children, fight bad health in them, and make them healthy and strong.
Gynofem Healthcare is a company with a mission to take care of the health of every mother and her child, and to keep them healthy.”
VISION STATEMENT
“Gynofem Healthcare Pvt. Ltd.’s vision is to provide innovative, high-technology products that will satisfy the needs of the patients in areas of Gynecology and Obstetrics. Gynofem Healthcare Pvt. Ltd. wishes to emerge as a technology-driven pharmaceutical company offering top-quality and cost-effective healthcare to people of this country.
Gynofem Healthcare is firmly committed to its vision. Technology, research, and Development are the highest priorities of the company. Gynofem policies are market-oriented, keeping in view the benefits of its consumers. Gynofem is committed to promoting class products.”
IPO Details
No information is provided by the company regarding the IPO plans of them. However, the Gynofem share price will likely become a key focus if the company decides to go public in the future, with market trends and investor sentiment influencing its potential valuation.
Dividend Details
No information is provided by the company regarding the Dividend.
Subsidiaries
No information is provided by the company regarding the Subsidiaries of the company.
Industry
The Indian pharmaceutical industry is booming. It jumped from $40 billion in 2021 to an expected $130 billion in 2030, with projections hitting $450 billion by 2047. Beyond just keeping up with the demand at home, the Indian pharma industry commands over 20% of the global pharma supply chain and addresses approximately 60% of the worldwide demand for vaccines.
It meets 40% of the generic demand in the US and provides a quarter of all medicines in the UK. It has undergone a remarkable transformation, evolving into a dynamic powerhouse driving healthcare advancements worldwide. Interestingly, India is the biggest contributor to UNESCO, with a share of over 50-60%. Plus, it boasts the highest number of USFDA-approved plants outside the U.S.
Fundamentals
Financials
All values are INR Cr except per share value
Revenue Growth
PAT Growth %
EPS Growth %
TOTAL ASSETS Growth %
QUICK RATIO Growth %
LONG TERM DEBT TO EQUITY RATIO Growth %
Frequently Asked Questions
Like any other financial product or commodity, the price of unlisted shares is discovered at the intersection of demand from buyers and supply from sellers of particular unlisted shares.
The two determinants of price are dynamic factors and keep changing constantly, hence share price tends to fluctuate constantly – every day, every minute.
Upon successful completion of a deal, the unlisted shares are credited electronically directly to your standard demat account that is usually created with CDSL or NSDL (Central Depository Services Limited or National Securities Depository Limited).
The lock-in period of Gynofem Healthcare varies depending on the category of the investor:
-
Venture capital or foreign venture capital investors are subject to lock-in period of 6 months from the date of acquisition of shares
-
For AIF investors of Category-II are not subject to any lock-in.
-
Any other investor, including retail investors, HNI or corporate investors are subject to a lock-in period of 6 months from the date of listing.
Note – The above-mentioned lock-in is for mainboard, however for SME IPO the applicable lock-in period is 1 Year.
There is no regulatory minimum limit to invest in unlisted shares. However, minimum investment size varies with the per share price. Earlier, the typical investment size often ranges between 70K – 100K, but with the growing awareness and increased participation the investment size has been down sized to 50k.
Short-Term Capital Gain tax is applicable when you sell your unlisted shares within a year from date of acquisition. Realized gain is taxable at your slab rate after consolidating in total income for the year. Hence, the rate of tax depends on your overall income for the particular financial year.
Long-Term Capital Gain taxes are applicable when you sell your unlisted shares after two years from the date of acquisition. LTCG tax is calculated on profits realized on sale of unlisted shares at 12.5%. Investors particularly retail or HNI must understand the concept clearly as it impacts strategy and tax planning.
-
You can download the NSDL or CDSL application and login into the account and check whether the shares have been credited or not.
-
Credit of Unlisted Shares/Pre-IPO shares can be checked in brokers application as well but it takes T+2 days to show the shares.
-
You would also get email confirmation of credit of shares via email
-
The value of share in unlisted space is determined in the same way as it is done in the listed market. Demand and supply decide the price of any share. If the demand is more than the supply, then the price of the share increases and vice versa.
-
When a new share is introduced in the unlisted space, the value of the company is decided upon the last funding raised by the company. If the company hasn’t raised any funding in the past, then the valuation is decided upon the fundamentals of the company.
Yes, investing in unlisted shares is legal in India, the activity is regulated and governed under the rules and guidelines laid by SEBI (Securities and Exchange Board of India). Related parties must comply with the regulations and guidelines to ensure legal and financial standards.
Investing in unlisted shares in India carries a significant and distinctive risk profile such as limited liquidity, lack of transparent pricing and regulatory oversight because unlisted shares do not trade on listed stock exchange, they are bought or sold in OTC (over the counter) market that makes vulnerable to following risks:
-
Liquidity risk, unlisted shares are difficult to buy and sell,
-
Lack of transparent pricing, as share price of pre-IPO or unl;isted company is often determined by narrative not fundamentals
-
Lack of information disclosure, unlisted companies are not mandated for disclosures like listed companies
-
Tax ambiguity, because determination of fair market value and cost of acquisition of unlisted shares is often disputed
Hence, investors should carefully examine related facts before investing in Pre-IPO or unlisted shares.